CAJ | 학술논문

[目的]观察羟考酮缓释片在多西他赛二线治疗伴随疼痛的晚期肺癌患者的疗效及安全性。[方法]对2007年2月-2011年7月收治的40例中、重度肿瘤疼痛者采用羟考酮缓释片止痛，同时予多西他赛75 mg/m2静脉滴注1 h，第1天，每3周重复。观察治疗前后疗效、不良反应及生活质量评分。[结果]有效率27．5％，疾病控制率60％，中位生存期9．35个月，1年生存率37．5％。与治疗前比较，患者疼痛程度有较大的缓解，疼痛缓解率为97．5％，数字模拟评分法（NRS）评分明显降低，KPS评分明显升高，差异均具有统计学意义（P＜0．05）。不良反应主要是血液学毒性和便秘，治疗后可以缓解。[结论]羟考酮缓释片联合多西他赛治疗中重度疼痛的肺癌安全有效，能明显改善病人的生活质量。
[목적]관찰간고동완석편재다서타새이선치료반수동통적만기폐암환자적료효급안전성。[방법]대2007년2월-2011년7월수치적40례중、중도종류동통자채용간고동완석편지통，동시여다서타새75 mg/m2정맥적주1 h，제1천，매3주중복。관찰치료전후료효、불량반응급생활질량평분。[결과]유효솔27．5％，질병공제솔60％，중위생존기9．35개월，1년생존솔37．5％。여치료전비교，환자동통정도유교대적완해，동통완해솔위97．5％，수자모의평분법（NRS）평분명현강저，KPS평분명현승고，차이균구유통계학의의（P＜0．05）。불량반응주요시혈액학독성화편비，치료후가이완해。[결론]간고동완석편연합다서타새치료중중도동통적폐암안전유효，능명현개선병인적생활질량。
[Objective] To evaluate the efficacy and safety of oxycodone controlled-release tablets in patients with advanced non-small cell lung cancer ( NSCLC ) who suffered from cancer pain and needed the treatment of docetaxel as second-line drug. [Methods] Data from 40 patients with NSCLC who suf-fered from moderate and severe cancer pain and were treated with oxycodone controlled -release tablets and docetaxel 75mg/m2 on d1 every 3 weeks from Feb 2007 to July 2011.The analgesic effects, karnofsky per-formance status scales ( KPS) and adverse effects were observed . [ Results] A group of 40 patients were available for evaluation, of whom the response rate was 27.5%,the disease control rate 60%,and the medi-an survival of all 9.35 months, with one-year survival rate being 37.5%.Compared with the condition be-fore treatment, pain in patients was greatly relieved , and the total pain relief rate was 97.5%,with the NRS score decreased significantly , and KPS score significantly raised , whose differences were statistically signifi-cant (P<0.05).The main side effect was hematologic toxicity and constipation , which could be solved af-ter treatment. [ Conclusion] Oxycodone combined with Docetaxel has satisfactory efficacy for the pa-tients with moderate to severe pain in NSCLC , thus markedly improving the quality of life of the patients .